Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression
Dolina, J. S.; Lee, J.; Brightman, S. E.; McArdle, S.; Hall, S. M.; Thota, R. R.; Lanka, M.; Premlal, A. L. R.; Greenbaum, J. A.; Cohen, E. E. W.; Peters, B.; Schoenberger, S. P.
Show abstract
Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor mutational burden (TMB) to allow for the spontaneous recognition of neoantigens (NeoAg) by autologous T cells. We explored whether the response of an aggressive low TMB squamous cell tumor to ICB could be improved through combination immunotherapy using functionally defined NeoAg as targets for endogenous CD4+ and CD8+ T cells. We found that, whereas vaccination with CD4+ or CD8+ NeoAg alone did not offer prophylactic or therapeutic immunity, vaccines containing NeoAg recognized by both subsets overcame ICB resistance and led to the eradication of large established tumors that contained a subset of PD-L1+ tumor-initiating cancer stem cells (tCSC), provided the relevant epitopes were physically linked. Therapeutic CD4+/CD8+ T cell NeoAg vaccination produced a modified tumor microenvironment (TME) with increased numbers of NeoAg-specific CD8+ T cells existing in progenitor and intermediate exhausted states enabled by combination ICB-mediated intermolecular epitope spreading. The concepts explored herein should be exploited for the development of more potent personalized cancer vaccines that can expand the range of tumors treatable with ICB.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Intratumor Childhood Vaccine-Specific CD4+ T cell Recall Coordinates Antitumor CD8+ T cells and Eosinophils 97%
- Distinct sets of molecular characteristics define tumor-rejecting neoantigens 97%
- The spontaneous neoantigen-specific CD4+ T cell response to a growing tumor is functionally and phenotypically diverse. 97%
Similar papers in this journal
- Cellular selectivity of STING stimulation determines priming of tumor-specific T cell responses 97%
- A reservoir of stem-like CD8 T cells in the tumor-draining lymph node maintains the ongoing anti-tumor immune response 96%
- Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4+ T cell response 96%
Similar papers in this journal
- IL-3-driven T cell-basophil crosstalk enhances anti-tumor immunity 96%
- The conventional dendritic cell 1 subset primes CD8+ T cells and traffics tumor antigen to drive anti-tumor immunity in the brain 96%
- Targeting macrophages with CAR-T cells delays solid tumor progression and enhances anti-tumor immunity 96%
Similar papers in this journal
- TGF--dependent Lymphoid Tissue Residency of Stem-like T cells Limits the Response to Tumor Vaccine 97%
- Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC 97%
- Rapid establishment of a tumor-retained state curtails the contribution of conventional NK cells to anti-tumor immunity in solid cancers 96%
Similar papers in this journal
- Diverse priming outcomes under conditions of very rare precursor B cells 96%
- IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy 95%
- Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.